Lexeo Therapeutics, Inc.’s (NASDAQ:LXEO) Lock-Up Period To Expire on May 1st

Lexeo Therapeutics’ (NASDAQ:LXEO) lock-up period is set to expire on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the end of Lexeo Therapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Lexeo Therapeutics Price Performance

Shares of LXEO stock opened at $12.14 on Wednesday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a one year low of $9.00 and a one year high of $22.33. The company’s 50-day moving average price is $14.48.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). Analysts predict that Lexeo Therapeutics will post -3.03 earnings per share for the current year.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently made changes to their positions in the stock. Eventide Asset Management LLC bought a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $40,298,000. Omega Fund Management LLC bought a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $28,955,000. Finally, Blackstone Inc. purchased a new stake in Lexeo Therapeutics during the 4th quarter valued at $9,342,000. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.